AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23892777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 22802308 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg per day) for 3 months
Number of subjects: 44
Study 22802308 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg per day) for 3 months
Number of subjects: 44
Study 19874198 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg
Number of subjects: 0
Study 19874198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19874198 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (all doses)
Number of subjects: 0
Study 19874198 — intervention group
Group type: COMPARATOR
Intervention: Odanacatib and Placebo
Number of subjects: 0
Study 18310545 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone and rituximab
Number of subjects: 0
Study 18310545 — intervention group
Group type: COMPARATOR
Intervention: High dose methylprednisolone alone
Number of subjects: 0
Study 15847901 — intervention group
Group type: EXPERIMENTAL
Intervention: Safehip hip protectors
Number of subjects: 109
Study 15847901 — intervention group
Group type: COMPARATOR
Intervention: HipSaver hip protectors
Number of subjects: 109
Study 15847901 — intervention group
Group type: COMPARATOR
Intervention: Safehip and HipSaver hip protectors
Number of subjects: 109
Study 15847901 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents in a home for the elderly mentally infirm
Number of subjects: 109
Study 15847901 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with a low Barthel score (12 or less)
Number of subjects: 109
Study 15847901 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with a history of falls in the last 12 months
Number of subjects: 109
Study 12209697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha2b (HDI)
Number of subjects: 148
Study 12209697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon alpha2b (LDI)
Number of subjects: 148
Study 12209697 — intervention group
Group type: COMPARATOR
Intervention: Standard observation (OBS)
Number of subjects: 148
Study 12209697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha2b (HDI) and Low-dose interferon alpha2b (LDI)
Number of subjects: 148
Study 10522576 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (15 mL bupivacaine 0.5%) and 1 mL normal saline i.v. (FNB group)
Number of subjects: 90
Study 10522576 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg (1 mL) ketorolac i.v. (KT group)
Number of subjects: 90
Study 10522576 — intervention group
Group type: COMPARATOR
Intervention: Placebo femoral nerve block (15 mL normal saline) and 1 mL normal saline i.v. (PL group)
Number of subjects: 90
Study 7747819 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 beta (rhuIL-1 beta) at high concentration (1.0 micrograms/cm2/day)
Number of subjects: 26
Study 7747819 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 beta (rhuIL-1 beta) at low (0.01 micrograms/cm2/day) and medium (0.1 micrograms/cm2/day) concentrations
Number of subjects: 26
Study 7747819 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue culture measurements from pressure ulcer biopsies
Number of subjects: 26
Study 1970552 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of an i.v. immunoglobulin preparation (ivIg)/kg body weight every other week
Number of subjects: 40
Study 1970552 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40
Study 517996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent tourniquet release with 5 seconds deflation (group I)
Number of subjects: 25
Study 517996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent tourniquet release with 30 seconds deflation (group II)
Number of subjects: 25
Study 517996 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet released at once (group III)
Number of subjects: 25
Study 30969452 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking joint pain medication
Number of subjects: 1294
Study 30969452 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1294
Study 30969452 — intervention group
Group type: EXPERIMENTAL
Intervention: More education
Number of subjects: 1294
Study 30969452 — intervention group
Group type: EXPERIMENTAL
Intervention: Better ability to cope economically
Number of subjects: 1294
Study 30969452 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1294
Study 30969452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to cope economically
Number of subjects: 1294
Study 27329923 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with House Dust Mite allergen extract
Number of subjects: 42
Study 27329923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25728723 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-delivered DASH/SRD-compliant meals
Number of subjects: 66
Study 25728723 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary advice
Number of subjects: 66
Study 23376799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine, clevudine)
Number of subjects: 124
Study 23376799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues
Number of subjects: 124
Study 21992121 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBF 1120 150 mg twice a day
Number of subjects: 432
Study 21992121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 19784512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dexa)
Number of subjects: 77
Study 19784512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (Onda)
Number of subjects: 77
Study 19784512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Ondansetron (Dexa+Onda)
Number of subjects: 77
Study 19784512 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cont)
Number of subjects: 77
Study 17116064 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of placental delivery at 20 minutes
Number of subjects: 1607
Study 17116064 — intervention group
Group type: COMPARATOR
Intervention: Timing of placental delivery at 30 minutes
Number of subjects: 1607
Study 12457048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital alert system for hospital staff
Number of subjects: 606
Study 12457048 — intervention group
Group type: COMPARATOR
Intervention: GP alert system for community general practitioners
Number of subjects: 606
Study 10767815 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vigorous medical exercise therapy (8-week active rehabilitation program with vigorous lumbar stabilizing exercises)
Number of subjects: 63
Study 10767815 — intervention group
Group type: COMPARATOR
Intervention: Control group (mild program of 2 to 3 back exercises at home after 2 months of rest)
Number of subjects: 63
Study 9370387 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg twice daily
Number of subjects: 16
Study 9370387 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD 300 mg daily
Number of subjects: 16
Study 8459956 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum curettage
Number of subjects: 32
Study 8459956 — intervention group
Group type: COMPARATOR
Intervention: No curettage (Control)
Number of subjects: 32
Study 3943266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoxin (0.5 mg)
Number of subjects: 13
Study 3943266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoxicaps (0.4 mg)
Number of subjects: 13
Study 30923022 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages targeted to primary care patients and tailored to quit readiness
Number of subjects: 0
Study 30923022 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week supply of nicotine patches and/or lozenges (NRT)
Number of subjects: 0
Study 30923022 — intervention group
Group type: EXPERIMENTAL
Intervention: Both text messaging and NRT
Number of subjects: 0
Study 30923022 — intervention group
Group type: COMPARATOR
Intervention: Brief advice only
Number of subjects: 0
Study 29277895 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (ENZ) and CCX771 (CXCR7 inhibitor) combination treatment
Number of subjects: 2
Study 29277895 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide (ENZ)
Number of subjects: 2
Study 29277895 — intervention group
Group type: COMPARATOR
Intervention: CCX771 (CXCR7 inhibitor)
Number of subjects: 2
Study 25403681 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 134
Study 25403681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 25403681 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (for those who achieved complete response)
Number of subjects: 134
Study 22447495 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-D (Cognitive Therapy targeting overestimations of danger)
Number of subjects: 78
Study 22447495 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-R (Cognitive Therapy targeting inflated beliefs of personal responsibility)
Number of subjects: 78
Study 20735804 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium sulfide shampoo 1%
Number of subjects: 40
Study 20735804 — intervention group
Group type: COMPARATOR
Intervention: Ciclopirox shampoo 1%
Number of subjects: 40
Study 16896962 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg)
Number of subjects: 54
Study 16896962 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 54
Study 15022148 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 1841
Study 15022148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1841
Study 11787924 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17‐beta oestradiol 50 microg/day for 21 days (cyclical therapy)
Number of subjects: 2
Study 11787924 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal 17‐beta oestradiol 50 microg/day
Number of subjects: 2
Study 9480174 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dependent diabetes mellitus (IDDM)
Number of subjects: 67
Study 9480174 — intervention group
Group type: EXPERIMENTAL
Intervention: Non insulin dependent diabetes mellitus (NIDDM)
Number of subjects: 67
Study 9480174 — intervention group
Group type: COMPARATOR
Intervention: Control group (non diabetic patients with ischaemic heart disease)
Number of subjects: 67
Study 9480174 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 67
Study 8320575 — intervention group
Group type: COMPARATOR
Intervention: Routine computer reminders (control)
Number of subjects: 5407
Study 8320575 — intervention group
Group type: EXPERIMENTAL
Intervention: Required to circle one of four responses to computer reminders
Number of subjects: 5407
Study 3624124 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 6
Study 3624124 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 6
Study 31431080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous microwave ablation
Number of subjects: 32
Study 31431080 — intervention group
Group type: COMPARATOR
Intervention: No oxytocin (control)
Number of subjects: 32
Study 29970818 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for planning coverage paths for fixed-wing UAVs that accounts for wind and decomposes regions into convex polygons.
Number of subjects: 0
Study 29970818 — intervention group
Group type: COMPARATOR
Intervention: Previous coverage path planning techniques without wind consideration.
Number of subjects: 0
Study 27533305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 20
Study 27533305 — intervention group
Group type: COMPARATOR
Intervention: Isoglycemic intravenous glucose infusion (IIGI)
Number of subjects: 20
Study 27533305 — intervention group
Group type: EXPERIMENTAL
Intervention: IIGI with glucagon infusion (0.8 ng/kg/min from 0 to 25 minutes)
Number of subjects: 20
Study 24857100 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin/paclitaxel X 5 and 41.4 Gy concurrent radiotherapy followed by surgery
Number of subjects: 0
Study 24857100 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 21332855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with ice in a plastic bag (3 sessions of 10 minutes each over 3 hours)
Number of subjects: 59
Study 21332855 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy (control group)
Number of subjects: 59
Study 20975104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular-weight (HMW) carbohydrate solution
Number of subjects: 6
Study 20975104 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight (LMW) carbohydrate solution
Number of subjects: 6
Study 20975104 — intervention group
Group type: COMPARATOR
Intervention: Flavored water (WAT)
Number of subjects: 6
Study 20975104 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between HMW and LMW solutions
Number of subjects: 6
Study 17953788 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) 2g
Number of subjects: 8
Study 17953788 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) 5g
Number of subjects: 8
Study 17953788 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) 10g
Number of subjects: 8
Study 17953788 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) 15g
Number of subjects: 8
Study 17953788 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) (all doses)
Number of subjects: 8
Study 17953788 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) (15g)
Number of subjects: 8
Study 16514811 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (a long‐acting garlic drug) for 12 months
Number of subjects: 167
Study 14690159 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1500 mg
Number of subjects: 63
Study 14690159 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 900 mg
Number of subjects: 63
Study 14690159 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 90 mg
Number of subjects: 63
Study 11778280 — intervention group
Group type: EXPERIMENTAL
Intervention: HLF regimen (hydroxycamptothecin HCPT/leucovorin LV/fluorouracil 5‐Fu)
Number of subjects: 48
Study 11778280 — intervention group
Group type: COMPARATOR
Intervention: ELF regimen (etoposide VP‐16/LV/5‐Fu)
Number of subjects: 48
Study 11778280 — intervention group
Group type: EXPERIMENTAL
Intervention: HLF regimen
Number of subjects: 48
Study 9059473 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled salbutamol for four weeks
Number of subjects: 30
Study 9059473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20058472 — intervention group
Group type: EXPERIMENTAL
Intervention: Alligator plate fixation
Number of subjects: 17
Study 20058472 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation (cerclage)
Number of subjects: 17
Study 3571097 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate (LCHO) 45 g
Number of subjects: 10
Study 3571097 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid carbohydrate confectionery bar (SCHO) 45 g
Number of subjects: 10
Study 3571097 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO meal (200 g) + Solid carbohydrate confectionery bar (M + SCHO)
Number of subjects: 10
Study 3571097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 30453477 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tryptophan intake
Number of subjects: 873
Study 30453477 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily protein intake
Number of subjects: 873
Study 30453477 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily energy intake
Number of subjects: 873
Study 30453477 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum transthyretin (TTR)
Number of subjects: 873
Study 30453477 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum insulin-like growth factor-1 (IGF-1)
Number of subjects: 873
Study 27391450 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental tree monocultures and secondary forests
Number of subjects: 0
Study 25403703 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal coronary sinus pacing
Number of subjects: 0
Study 25403703 — intervention group
Group type: COMPARATOR
Intervention: Right atrial appendage pacing
Number of subjects: 0
Study 22963997 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief pulse ECT
Number of subjects: 150
Study 22963997 — intervention group
Group type: COMPARATOR
Intervention: Ultrabrief pulse ECT
Number of subjects: 150
Study 20653695 — intervention group
Group type: EXPERIMENTAL
Intervention: nebicapone 150 mg
Number of subjects: 252
Study 20653695 — intervention group
Group type: EXPERIMENTAL
Intervention: entacapone 200 mg (active control)
Number of subjects: 252
Study 20653695 — intervention group
Group type: EXPERIMENTAL
Intervention: nebicapone 50 mg
Number of subjects: 252
Study 20653695 — intervention group
Group type: EXPERIMENTAL
Intervention: nebicapone 100 mg
Number of subjects: 252
Study 20653695 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 252
Study 18372941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre enriched semi-skimmed milk (20 grams of soluble fibre per day)
Number of subjects: 32
Study 18372941 — intervention group
Group type: COMPARATOR
Intervention: Semi-skimmed milk (control group)
Number of subjects: 32
Study 16332468 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral feedback intervention
Number of subjects: 161
Study 16332468 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 161
Study 11151264 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nonpreserved steroids for 2 weeks followed by punctal occlusion
Number of subjects: 30
Study 8656364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure patching after application of antibiotic/steroid ointment (A/S)
Number of subjects: 41
Study 8656364 — intervention group
Group type: COMPARATOR
Intervention: A/S ointment twice a day without patching
Number of subjects: 41
Study 1290331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lo-Estrin (norethindrone acetate 1.5 mg plus ethinyl estradiol 0.030 mg)
Number of subjects: 148
Study 1290331 — intervention group
Group type: COMPARATOR
Intervention: Lo-Femenal (norgestrel 0.30 mg plus ethinyl estradiol 0.030 mg)
Number of subjects: 148
Study 1290331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lo-Estrin
Number of subjects: 148
Study 1290331 — intervention group
Group type: COMPARATOR
Intervention: Lo-Femenal
Number of subjects: 148
Study 6721124 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg orally the night before operation and 1 mg on the morning of operation)
Number of subjects: 68
Study 6721124 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital (100 mg orally the night before operation) + Atropine (0.01 mg/kg intramuscular) + Pethidine (1 mg/kg intramuscular on the morning of operation)
Number of subjects: 68
Study 30421439 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 585
Study 30421439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585
Study 28639539 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision as an HIV prevention strategy
Number of subjects: 0
Study 28639539 — intervention group
Group type: EXPERIMENTAL
Intervention: Histo-immunological studies of the foreskin
Number of subjects: 0
Study 28639539 — intervention group
Group type: COMPARATOR
Intervention: Contextual differences in HIV transmission patterns
Number of subjects: 0
Study 28639539 — intervention group
Group type: COMPARATOR
Intervention: Conflicting scientific details regarding foreskin's susceptibility to HIV
Number of subjects: 0
Study 25535980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss
Number of subjects: 20
Study 25535980 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseous
Number of subjects: 20
Study 22627778 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone brief intervention (BI)
Number of subjects: 249
Study 22627778 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 249
Study 21784372 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 34
Study 21784372 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 34
Study 19514077 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBG scintigraphy
Number of subjects: 39
Study 19514077 — intervention group
Group type: COMPARATOR
Intervention: Abnormal AFT in PD
Number of subjects: 39
Study 19514077 — intervention group
Group type: COMPARATOR
Intervention: Abnormal AFT in MSA-p
Number of subjects: 39
Study 19514077 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and delayed H/M ratio
Number of subjects: 39
Study 16675212 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination (SFC) 50/250 microg one inhalation twice daily (bid)
Number of subjects: 1391
Study 16675212 — intervention group
Group type: COMPARATOR
Intervention: Formoterol/budesonide combination (FBC) 6/200 microg two inhalations bid
Number of subjects: 1391
Study 14702457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cygnus GlucoWatch biographer
Number of subjects: 45
Study 11379681 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane with 0% xenon (Group 1)
Number of subjects: 60
Study 11379681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 20% xenon (Group 2)
Number of subjects: 60
Study 11379681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 40% xenon (Group 3)
Number of subjects: 60
Study 11379681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% xenon (Group 4)
Number of subjects: 60
Study 9226601 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH‐A
Number of subjects: 10
Study 9226601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15449510 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hyaluronate/2.5 ml (verum)
Number of subjects: 209
Study 15449510 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg hyaluronate/2.5 ml (control)
Number of subjects: 209